We are live on ! Find out more
CASI

CASI Pharmaceuticals
CASI

Delisted

CASI was delisted on the 25th of February, 2026.

Back to rankings

51 hedge funds and large institutions have $22.4M invested in CASI Pharmaceuticals in 2021 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 9 increasing their positions, 15 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.77% less ownership

Funds ownership: 2.77% → 2% (-0.77%)

12% less funds holding

Funds holding: 58 → 51 (-7)

38% less first-time investments, than exits

New positions opened: 10 | Existing positions closed: 16

40% less repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 15

51% less capital invested

Capital invested by funds: $46M → $22.4M (-$23.7M)

100% less funds holding in top 10

Funds holding in top 10: 1 → 0 (-1)

Holders
51
Holders Change
-7
Holders Change %
-12.07%
% of All Funds
0.78%
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
10
Increased
9
Reduced
15
Closed
16
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
+$943K
2
Franklin Resources
Franklin Resources
California
+$359K
3
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$298K
4
AFM
Anson Funds Management
Texas
+$266K
5
Geode Capital Management
Geode Capital Management
Massachusetts
+$195K

Top Sellers

1
CCM
Consonance Capital Management
New York
-$1.86M
2
GTC
Ghost Tree Capital
New York
-$774K
3
WSC
Wellington Shields & Co
New York
-$689K
4
Marshall Wace
Marshall Wace
United Kingdom
-$649K
5
Millennium Management
Millennium Management
New York
-$431K
Name Holding Trade Value Shares
Change 		Change in
Stake
CSS
51
Cubist Systematic Strategies
Connecticut
– -$260K -21,843 Closed
T. Rowe Price Associates
52
T. Rowe Price Associates
Maryland
– -$104K -8,750 Closed
1CM
53
1492 Capital Management
Wisconsin
– -$94K -7,876 Closed
HF
54
HRT Financial
New York
– -$77K -6,535 Closed
XT
55
XTX Topco
Cayman Islands
– -$49K -4,132 Closed
BCM
56
Bridgeway Capital Management
Texas
– -$40K -3,340 Closed
SSA
57
Schonfeld Strategic Advisors
New York
– -$24K -1,960 Closed
MHP
58
Manatuck Hill Partners
Connecticut
– -$18K -1,509 Closed
Qube Research & Technologies (QRT)
59
Qube Research & Technologies (QRT)
United Kingdom
– -$13K -1,051 Closed
WANY
60
Wealthspire Advisors (New York)
New York
– -$12K -1,000 Closed
Barclays
61
Barclays
United Kingdom
– -$12K -976 Closed
JP Morgan Chase
62
JP Morgan Chase
New York
– -$6.88K -691 -96%
MAM
63
Meeder Asset Management
Ohio
– -$5K -407 Closed
TCWM
64
Total Clarity Wealth Management
Illinois
– -$2K -200 Closed
SWM
65
Selective Wealth Management
Virginia
– +$10 +1 New
1 2
3

CASI Hedge Fund Activity: Q4 2021 in Review

51 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in CASI Pharmaceuticals (CASI) for Q4 2021, worth a combined $22.4M — down 51% from $46M a quarter earlier.

Sellers outnumbered buyers: 16 funds closed out of CASI and 10 opened new positions — a net loss of 6 holders — while 15 trimmed existing stakes and 9 added.

The largest buyer was Jacobs Levy Equity Management, adding an estimated $943K. The largest seller was Consonance Capital Management, exiting entirely with an estimated $1.86M sold.

  • 51 institutional investors held CASI Pharmaceuticals (CASI) as of Q4 2021, down from 58 in Q3 2021.
  • Funds reported $22.4M of CASI Pharmaceuticals stock for Q4 2021, down 51% quarter-over-quarter.
  • 10 funds opened new CASI Pharmaceuticals positions in Q4 2021 and 16 closed out, a net change of -6 holders.
  • The largest CASI Pharmaceuticals buyer in Q4 2021 was Jacobs Levy Equity Management, an estimated $943K added.
  • The largest CASI Pharmaceuticals seller in Q4 2021 was Consonance Capital Management, an estimated $1.86M sold.

Based on aggregated 13F filings for Q4 2021.